Core Viewpoint - The report from Guosen Securities indicates that the medical services and consumer-related sectors have experienced long-term adjustments, resulting in valuations at historical lows. By 2026, improvements in supply structure, increased treatment volumes, and store optimization are expected to lead to a dual recovery in fundamentals and valuations, with AI empowerment providing new momentum for leading companies [1][2]. Group 1: Medical Services and Consumer Sectors - The medical services and consumer-related sectors are currently undervalued and poised for performance recovery, with a focus on specific sub-sectors [2]. - In medical services, improvements in supply structure and consumer environment are anticipated to gradually revive business, with stable customer spending and increased treatment volumes. Leading companies are expected to provide positive earnings guidance for 2026, indicating a potential dual recovery in fundamentals and valuations. AI-related business developments are also expected to drive new growth for leading medical service firms. Key companies to watch include Aier Eye Hospital (300015), Gushengtang, Tongce Medical (600763), and Haijia Medical [2]. - The pharmacy sector has shown significant marginal improvement in performance since Q3 2025, with leading companies improving same-store performance quarterly. Regulatory support from nine ministries emphasizes the long-term development direction of industry concentration and chain rate enhancement, with non-pharmaceutical adjustments and store structure optimization driving short-term performance improvements. Key companies include Yifeng Pharmacy (603939) and Dazhenglin (603233) [2]. Group 2: Home Medical Devices - The growth of home medical device companies is driven by increased product penetration and domestic production rates. Rapid growth is observed in products like Continuous Glucose Monitors (CGM) and sleep apnea machines, with leading domestic brands expanding internationally. Traditional categories like blood pressure monitors are increasingly focusing on the high-end market, with domestic brands steadily increasing market share. The combination of high domestic growth and new overseas markets is expected to contribute to sustained performance growth for home medical device companies. Key companies include Yuyue Medical (002223), Kefu Medical (301087), Sanofi Biological (300298), and Ruimaite (301367) [3]. Group 3: Innovative Drug Development - The collaboration for the international expansion of innovative drugs continues to deepen, with recent significant agreements between Shiyao Group and AstraZeneca, as well as Innovent Biologics and Eli Lilly. These collaborations highlight the growing recognition of China's innovative drug development capabilities by multinational pharmaceutical companies, showcasing the efficiency and cost advantages of Chinese innovative drugs [4]. Group 4: Investment Portfolio for 2026 - The investment portfolio for 2026 includes A-shares such as Mindray Medical (300760), United Imaging Healthcare, WuXi AppTec (603259), New Industry (300832), Meihua Medical (301363), Adebiotech (300685), Zhend Medical (603301), Yaokang Biological, Kingmed Diagnostics (603882), Aier Eye Hospital, Yuyue Medical, Yifeng Pharmacy, and Dazhenglin; H-shares include Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi Biopharma, Gushengtang, and Aikang Medical [5].

Core Insights - The report emphasizes the focus on undervalued and performance-recovering sectors within the medical services and consumer segments, predicting a fundamental improvement in 2026 [4]. Group 1: Investment Strategy - The report maintains an "outperform" rating for the sector, indicating a positive outlook for the medical and consumer-related segments [2]. - Key areas of focus include medical services, pharmacies, and home medical devices, which are expected to see performance recovery and valuation improvements in 2026 [4]. Group 2: Sector Analysis - Medical services are anticipated to recover due to improved supply structure and consumer environment, with leading companies expected to show positive earnings guidance for 2026 [4]. - The pharmacy sector has shown significant marginal improvement since Q3 2025, with leading companies experiencing quarterly performance enhancements [4]. - Home medical devices are expected to benefit from increased product penetration and domestic production rates, contributing to sustained performance growth [4]. Group 3: Notable Companies - The report highlights specific companies to watch, including Aier Eye Hospital, Yuyue Medical, and Yifeng Pharmacy, which are positioned for growth in their respective segments [4]. - The investment portfolio for February 2026 includes a mix of A-share and H-share companies, such as Mindray Medical, WuXi AppTec, and Kangfang Biotech, indicating a diversified approach to investment [4]. Group 4: Market Performance - The medical sector outperformed the broader market in January 2026, with a 3.14% increase compared to the 1.49% rise of the CSI 300 index [10]. - Sub-sectors such as medical services and medical devices showed significant gains, with respective increases of 8.82% and 5.28% [17]. Group 5: Macro Data - In 2025, the pharmaceutical manufacturing industry reported a total revenue of 24,870 billion yuan, reflecting a slight decline of 1.2% year-on-year, while total profits increased by 2.7% [9]. - The retail sales of pharmaceuticals reached 7,294 billion yuan, with a year-on-year growth of 1.8%, indicating a stable demand in the market [9].

Investment Rating - The industry investment rating is "Overweight (Maintain)" [4] Core Insights - The recent results of the national centralized procurement for batches 1-8 have been released, which is expected to benefit leading companies with scale effects, particularly those integrated in raw material and formulation production [6] - The procurement process involved 5.1 million medical institutions and 1,091 domestic and foreign companies, with 4,163 products selected from 1,020 companies, indicating a high participation rate and a stable supply of selected products [6] - The procurement cycle is set to last until the end of 2028, allowing selected companies to secure a three-year national market, which is beneficial for capacity planning and cost optimization [6] Summary by Sections Industry Overview - The industry comprises 502 listed companies with a total market value of 73,023.15 billion yuan and a circulating market value of 67,026.08 billion yuan [2] Procurement Results - The procurement covers 316 commonly used drugs across 26 therapeutic areas, with a high selection rate of 93% for participating companies [6] - The average number of selected companies per product is 14, ensuring a diverse supply base and rich clinical choices [6] Competitive Landscape - The procurement reflects a shift in policy from "price reduction and expansion" to "price stability and quality assurance," favoring leading companies with compliance capabilities and scale advantages [6] - Companies like Huahai Pharmaceutical and Kelun Pharmaceutical have significant advantages in their respective fields, with high selection rates for major products [6] Future Outlook - The procurement process is expected to stabilize prices and industry expectations, moving the focus from "lowest price competition" to a comprehensive competition based on quality, capacity, compliance, and brand [6] - The new requirements for production experience and compliance are likely to accelerate the exit of smaller, weaker companies from the market [6]

传媒板块大涨，数字王国大涨29%，阅文集团涨逾15%，大麦娱乐涨超6%。 | 名称 | 涨跌幅 ▼ | 现价 | | --- | --- | --- | | 数字于国 | 29.31% | 0.375c | | 毛记葵涌 | 21.92% | 0.890c | | 万咖膏联 | 20.00% | 1.560c | | 中国国家文化产业 | 18.18% | 0.780c | | 阅文集团 | 15.41% | 43.580c | | 环球数码创意 | 9.09% | 0.072c | | 普乐师集团控股 | 8.76% | 5.710c | | 橙天嘉禾 | 7.81% | 0.069c | | 大麦娱乐 | 6.12% | 1.040c | | 新传企划 | 5.71% | 0.370c | | 中国儒意 | 5.63% | 2.250c | | 柠萌影视 | 5.42% | 3.500c | | 乐思集团 | 4.81% | 1.090c | | 丰德丽控股 | 4.17% | 0.050c | | 稻草熊娱乐 | 3.75% | 0.415c | | 大象未来集团 | 3.72% | 2.230c | ...

Core Viewpoint - The Hong Kong Dividend ETF (工银, 159691) has experienced significant net redemptions recently, indicating potential investor concerns or shifts in market sentiment [1][2]. Group 1: Fund Performance - As of February 10, the latest scale of the Hong Kong Dividend ETF (工银, 159691) is 8.78 billion yuan, with a net outflow of 27.79 million yuan on that day, representing 0.32% of the previous day's scale [1]. - Over the past five days, the fund has seen net redemptions totaling 70.53 million yuan, ranking 11th out of 215 in cross-border ETF net outflows [1]. - Year-to-date, the fund's shares have decreased by 4.58%, while its scale has increased by 4.09% compared to the end of 2025 [2]. Group 2: Trading Activity - The cumulative trading amount for the Hong Kong Dividend ETF (工银, 159691) over the last 20 trading days is 7.123 billion yuan, with an average daily trading amount of 356 million yuan [2]. - Since the beginning of the year, the fund has recorded a cumulative trading amount of 9.096 billion yuan over 27 trading days, averaging 337 million yuan per day [2]. Group 3: Fund Holdings - The top holdings of the Hong Kong Dividend ETF (工银, 159691) include China National Offshore Oil Corporation (14.55%), China Shenhua Energy Company (9.65%), and China Pacific Insurance (8.90%), among others [3]. - The fund's significant holdings reflect a diversified investment strategy focused on high-dividend stocks within the Hong Kong market [3].

2月10日，三大指数涨跌不一，创新药板块表现强势。截至当日收盘，恒生沪深港创新药精选50指数 (HSSSHID.HK)上涨2.26%收获六连阳，该指数成分股中，信立泰上涨近7%，石药集团与荣昌生物 （A）上涨超5%，信达生物上涨近5%。 海通国际证券指出，港股医药板块经历前期连续调整后，市场情绪有所回暖。随着港股业绩期临近，我 们看好业绩确定性强的互联网医疗、CXO/科研服务龙头。此外，我们建议持续关注本轮调整中回调幅 度较大的优质创新药龙头企业。 相关ETF方面，wind金融终端显示，截至当日收盘，创新药ETF天弘（517380）成交额超3700万元。资 金流向方面，截至2月9日，该ETF已连续3个交易日获资金净流入，累计净流入额为4166.12万元。该 ETF最新流通份额为25.04亿份，最新流通规模为19.63亿元。此外，生物医药ETF（159859）当日成交 额超1亿元，居同标的产品第一。该ETF最新流通份额为95.96亿份，最新流通规模为37.96亿元。 （文章来源：21世纪经济报道） 创新药ETF天弘（517380）为全市场唯一一只跟踪恒生沪港深创新药精选50指数的ETF，汇聚中国硬核 创新药力量 ...

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the performance of the Hong Kong stock market, particularly focusing on the Hang Seng Index and sector performances, including healthcare, consumer goods, and real estate [1][2]. Core Insights and Arguments - The Hang Seng Index increased by 0.5%, with the National Enterprises Index and Technology Index both rising by 0.8% [1] - The healthcare sector led the market with a gain of 3.0%, while consumer staples and real estate sectors lagged, declining by 0.5% and 0.6% respectively [1] - Total trading volume reached HKD 13.4 billion, with a net inflow of USD 147 million from southbound trading [1] - Despite a lack of strong catalysts, market momentum and liquidity remained positive, with investors cautious ahead of the upcoming long holiday [1] Sector-Specific Performance - The biotechnology and artificial intelligence sectors outperformed the market, while the tourism sector underperformed despite seasonal catalysts related to the Spring Festival [2] - Notable stock movements included: - CSPC Pharmaceutical Group up by 6.3% - Fosun Pharma up by 5.6% - Innovent Biologics up by 5.3%, driven by collaboration news with Eli Lilly [2] - Innoscience, a semiconductor company, saw a 7.5% increase, supported by 15% of its trading volume coming from southbound investors [3] - Kuaishou rose by 1.6% after a previous decline, indicating technical support [3] Additional Important Insights - The trading desk showed a preference for buying defensive stocks such as insurance and logistics while selling off positions in cement and e-commerce sectors [2] - The interest in the "Monster" IP (Labubu) from Pop Mart saw a delivery volume exceeding 100 million pieces, although southbound investors were selling the stock [3] - The short interest in Pop Mart decreased to 8.1 times DTC, representing 18% of its free float [3]

Report Summary 1. Report Industry Investment Rating - Not provided in the given content 2. Core View - The news in the stock index futures market has become relatively quiet, and the market is in a pattern of oscillating with a slightly upward trend [1] 3. Summary by Relevant Catalogs 3.1. Stock Index Futures Data Tracking - On February 10, the closing prices and price changes of the four major stock index futures contracts varied: IF2602 rose 0.20%, IH2602 rose 0.40%, IC2602 fell 0.08%, and IM2602 rose 0.14%. The base spreads, trading volumes, and open interests of different contracts also showed different changes [1] - On the trading day, the total trading volume of stock index futures declined, indicating a decrease in investors' trading enthusiasm. Specifically, the total trading volume of IF decreased by 25,264 lots, IH by 11,858 lots, IC by 42,219 lots, and IM by 53,668 lots. In terms of open interest, the total open interest of IF decreased by 5,989 lots, IH by 2,409 lots, IC by 10,803 lots, and IM by 10,481 lots [1][2] 3.2. Position Changes of the Top 20 Members in Stock Index Futures - For different contracts of IF, IH, IC, and IM, the long - and short - position changes of the top 20 members showed different trends. For example, in the IF2602 contract, the long - position decreased by 4,945 lots and the short - position decreased by 3,944 lots [5] 3.3. Trend Intensity and Important Drivers - The trend intensity of IF and IH is 1, and that of IC and IM is also 1. The market showed a narrow - range consolidation throughout the day, the Shanghai Composite Index recorded six consecutive positive days, the AI application sector had a wave of daily limit, while the photovoltaic and large - consumption sectors were weak. A - share trading volume decreased from 2.27 trillion yuan the previous day to 2.12 trillion yuan [6] - The Hong Kong stock market oscillated and strengthened, with the biotechnology and cultural media sectors being active. The Hang Seng Index rose 0.58%, the Hang Seng Tech Index rose 0.62%, and the Hang Seng China Enterprises Index rose 0.81%. The market turnover decreased from HK$255.142 billion the previous day to HK$234.04 billion [7]

交易台 – 高盛香港市场综述 恒生指数 +0.6% 国企指数 +0.8% 科技指数 +0.6% 成交额：2340 亿港元 领涨板块：医疗保健 +2.1%，能源 +1.8%，材料 +1.3% 落后板块：公用事业 -0.5%，地产 -0.5%，信息技术 -0.3% 港股开盘表现强劲，但很快回吐涨幅，收盘仅小幅走高。 恒生指数一度逼近 27400 点关口，随后回落至 27 交易台 – 高盛香港市场综述 恒生指数 +0.6% 国企指数 +0.8% 科技指数 +0.6% 成交额：2340 亿港元 领涨板块：医疗保健 +2.1%，能源 +1.8%，材料 +1.3% 落后板块：公用事业 -0.5%，地产 -0.5%，信息技术 -0.3% 港股开盘表现强劲，但很快回吐涨幅，收盘仅小幅走高。 内地 A 股表现落后于 H 股，收盘仅小幅上涨。 资金流向方面，交易台买入倾向为2.2 倍，零售板块（泡泡玛特）的回补买盘以及保险板块（友邦保险）的部分买 入使交易台倾向偏多。 交易台今日在大型科技股上也获得了不错的买盘，买入阿里巴巴，同时在美团等股票上进行做空以部分抵消。 材料板块买入持续，紫金矿业和 MMG1208 持续有买盘。 除此 ...

Market Trends - The domestic market indices showed slight fluctuations, with the Shanghai Composite Index closing at 4,128.37, up by 0.13% [4] - During the period from February 2 to February 8, major indices experienced declines, with the Shanghai Composite Index down by 1.27% and the ChiNext Index down by 3.28% [7] Industry Insights - The non-bank financial sector is seeing a revision in underwriting regulatory guidelines, which is expected to enhance investment value in the sector [5] - The media industry is projected to continue its upward trend, driven by AI applications and IP ecosystems, with a 27.17% increase in the media index for 2025 [6] - The power equipment and new energy sector is focusing on the AIDC power revolution, with expectations for a significant increase in photovoltaic power utilization rates [8][19] - The agricultural sector is facing potential price adjustments in pig farming after a peak season, with current prices showing a downward trend [15][17] Company Analysis - Aide Technology is recognized as a leader in domestic spinal vertebral body shaping systems, benefiting from an aging population [22] - Tianfu Communication's 2025 performance forecast indicates a net profit of 1.88 to 2.15 billion yuan, driven by stable demand for optical devices [26] - Wolong Nuclear Materials anticipates a net profit of 1.1 to 1.18 billion yuan for 2025, with strong market demand across various business segments [28] Investment Recommendations - The report suggests focusing on companies that leverage AI applications and IP development, such as Kunlun Wanwei and Shanghai Film [9] - In the photovoltaic sector, companies like Aishuo and Longji Green Energy are recommended due to their technological advancements and market positioning [16][23] - For the copper connection market, companies like Wolong Nuclear Materials are highlighted for their strong growth potential in the telecommunications sector [28]